"Immunotoxins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
| Descriptor ID |
D000922
|
| MeSH Number(s) |
D12.776.124.790.651.114.580.450 D12.776.377.715.548.114.580.450 D27.888.569.271
|
| Concept/Terms |
Immunotoxins- Immunotoxins
- Cytotoxin-Antibody Conjugates
- Conjugates, Cytotoxin-Antibody
- Cytotoxin Antibody Conjugates
- Immunotoxin
- Antibody-Toxin Hybrids
- Antibody Toxin Hybrids
- Hybrids, Antibody-Toxin
- Affinotoxins
- Antibody-Toxin Conjugates
- Antibody Toxin Conjugates
- Conjugates, Antibody-Toxin
- Toxin-Antibody Conjugates
- Conjugates, Toxin-Antibody
- Toxin Antibody Conjugates
- Toxin-Antibody Hybrids
- Hybrids, Toxin-Antibody
- Toxin Antibody Hybrids
- Monoclonal Antibody-Toxin Conjugates
- Antibody-Toxin Conjugates, Monoclonal
- Conjugates, Monoclonal Antibody-Toxin
- Monoclonal Antibody Toxin Conjugates
Toxins, Chimeric- Toxins, Chimeric
- Chimeric Toxins
- Toxin Conjugates
- Conjugates, Toxin
- Toxin Carriers
- Carriers, Toxin
- Toxin Conjugate
- Conjugate, Toxin
- Chimeric Toxin
- Toxin, Chimeric
- Toxin Carrier
- Carrier, Toxin
|
Below are MeSH descriptors whose meaning is more general than "Immunotoxins".
Below are MeSH descriptors whose meaning is more specific than "Immunotoxins".
This graph shows the total number of publications written about "Immunotoxins" by people in this website by year, and whether "Immunotoxins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 0 | 5 |
| 1995 | 3 | 0 | 3 |
| 1996 | 2 | 2 | 4 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 1 | 4 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 5 | 1 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 2 | 3 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotoxins" by people in Profiles.
-
The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J. 2018 03 20; 8(3):33.
-
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 03; 25(2):136-145.
-
Pneumotoxicity associated with immune checkpoint inhibitor therapies. Curr Opin Pulm Med. 2017 07; 23(4):305-316.
-
Enhancing cytotoxicity of immunotoxins in AML. Blood. 2016 06 09; 127(23):2787-8.
-
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45.
-
Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies. Curr Hematol Malig Rep. 2015 Jun; 10(2):76-85.
-
Resimmune, an anti-CD3e recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015 Jun; 100(6):794-800.
-
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar 15; 21(6):1267-72.
-
iCaspase 9 Suicide Gene System. Methods Mol Biol. 2015; 1317:87-105.
-
Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014 Jun; 15(2):187-209.